Sun Pharmaceutical’s GL0034 study reveals promising obesity treatment outcomes

Sun Pharmaceutical Industries Limited unveiled data from its Phase 1 study of GL0034 (Utreglutide), targeting obesity in adults. The findings, presented at the 84th American ... Read More